Published in Blood on October 27, 2008
Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med (2010) 2.82
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
TALEN-based gene correction for epidermolysis bullosa. Mol Ther (2013) 1.84
Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol (2010) 1.62
Pharmacological mobilization of endogenous stem cells significantly promotes skin regeneration after full-thickness excision: the synergistic activity of AMD3100 and tacrolimus. J Invest Dermatol (2014) 1.61
PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci U S A (2011) 1.38
Inherited epidermolysis bullosa. Orphanet J Rare Dis (2010) 1.16
Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood (2010) 1.15
Human mesenchymal stem cell grafts enhance normal and impaired wound healing by recruiting existing endogenous tissue stem/progenitor cells. Stem Cells Transl Med (2012) 1.14
Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther (2009) 1.03
Novel molecular therapies for heritable skin disorders. J Invest Dermatol (2011) 1.03
Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue. Hum Gene Ther (2010) 0.99
A mouse model of generalized non-Herlitz junctional epidermolysis bullosa. J Invest Dermatol (2010) 0.99
Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice. Proc Natl Acad Sci U S A (2010) 0.98
Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. J Invest Dermatol (2013) 0.96
Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. Lancet (2013) 0.94
Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res Ther (2014) 0.89
Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases. Int Arch Med (2011) 0.88
Isolation and culture of adult epithelial stem cells from human skin. J Vis Exp (2011) 0.87
High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa. Mol Ther (2015) 0.86
Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol (2009) 0.86
Superficial dermal fibroblasts enhance basement membrane and epidermal barrier formation in tissue-engineered skin: implications for treatment of skin basement membrane disorders. Tissue Eng Part A (2013) 0.84
Dystrophic epidermolysis bullosa: a review. Clin Cosmet Investig Dermatol (2015) 0.84
Advances in understanding and treating dystrophic epidermolysis bullosa. F1000Prime Rep (2014) 0.83
Molecular therapeutics for heritable skin diseases. J Invest Dermatol (2012) 0.83
Hematopoietic stem cells are pluripotent and not just "hematopoietic". Blood Cells Mol Dis (2013) 0.83
Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy (2015) 0.79
Animal models of skin disease for drug discovery. Expert Opin Drug Discov (2013) 0.79
A new mouse model of junctional epidermolysis bullosa: the LAMB3 628G>A knockin mouse. J Invest Dermatol (2014) 0.79
Cell therapy in dermatology. Cold Spring Harb Perspect Med (2014) 0.77
Induced pluripotent stem cells in dermatology: potentials, advances, and limitations. Cold Spring Harb Perspect Med (2014) 0.77
Augmentation of cutaneous wound healing by pharmacologic mobilization of endogenous bone marrow stem cells. J Invest Dermatol (2014) 0.76
Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients. Stem Cells Dev (2015) 0.76
From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa. Mol Ther (2015) 0.75
Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa. Transl Res (2015) 0.75
Bone marrow cells can manipulate healing. Blood (2009) 0.75
Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis Res (2017) 0.75
From Mesoderm to Mesodermatology: Bone Marrow Mesenchymal Cells Heal Skin Wounds. Mol Ther (2015) 0.75
CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regen Med (2016) 0.75
Rapid generation of Col7a1(-/-) mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Lab Invest (2017) 0.75
Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol (2017) 0.75
Design and Characterization of a Human Monoclonal Antibody that Modulates Mutant Connexin 26 Hemichannels Implicated in Deafness and Skin Disorders. Front Mol Neurosci (2017) 0.75
Raising Awareness Among Healthcare Providers about Epidermolysis Bullosa and Advancing Toward a Cure. J Clin Aesthet Dermatol (2017) 0.75
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 24.00
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell (2001) 12.42
Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells (2007) 7.57
Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A (2007) 5.17
Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol (2008) 4.42
The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol (2008) 3.72
SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity. Blood (2005) 3.22
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med (2006) 3.11
Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol (2002) 2.71
Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells (2004) 2.70
CD150- side population cells represent a functionally distinct population of long-term hematopoietic stem cells. Blood (2007) 2.27
Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol (2006) 2.24
Stable nonviral genetic correction of inherited human skin disease. Nat Med (2002) 2.20
Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol (2003) 1.99
Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest (2003) 1.83
Mutation analysis and molecular genetics of epidermolysis bullosa. Matrix Biol (1999) 1.70
Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet (2002) 1.67
A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest (2008) 1.67
Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med (2004) 1.62
Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci (1999) 1.61
Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol (1993) 1.61
CD150- cells are transiently reconstituting multipotent progenitors with little or no stem cell activity. Blood (2008) 1.57
Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther (2007) 1.41
Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des (2005) 1.40
Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther (2004) 1.36
Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases. J Clin Invest (1992) 1.29
Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn (2007) 1.20
Hematopoietic cell therapy for metabolic disease. J Pediatr (2007) 1.17
In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med (2007) 1.16
A look to future directions in gene therapy research for monogenic diseases. PLoS Genet (2006) 1.11
Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther (2004) 1.08
Isolation, characterization, and culture of epithelial stem cells. Methods Mol Biol (2005) 1.06
Donor-derived cells and human graft-versus-host disease of the skin. Blood (2006) 1.01
Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum Mol Genet (2003) 1.01
Gene therapy in combination with tissue engineering to treat epidermolysis bullosa. Expert Opin Biol Ther (2006) 1.00
A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line. Hum Gene Ther (2002) 0.99
Epidermolysis bullosa: a genetic disease of altered cell adhesion and wound healing, and the possible clinical utility of topically applied thymosin beta4. Ann N Y Acad Sci (2007) 0.96
Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. Curr Dir Autoimmun (2008) 0.93
Graftskin therapy in epidermolysis bullosa. J Am Acad Dermatol (2003) 0.92
The host immune response is essential for the beneficial effect of adult stem cells after myocardial ischemia. Exp Hematol (2007) 0.85
Engraftment of bone marrow-derived epithelial cells. Stem Cell Rev (2005) 0.82
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med (2004) 7.10
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2004) 7.09
Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet (2007) 6.93
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med (2004) 6.26
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
Functional and evolutionary insights from the genomes of three parasitoid Nasonia species. Science (2010) 5.56
IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol (2007) 5.31
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood (2010) 4.02
Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest (2002) 3.90
A simplified laminin nomenclature. Matrix Biol (2005) 3.81
The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol (2008) 3.72
Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol (2007) 3.65
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood (2009) 3.62
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood (2003) 3.42
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science (2010) 3.31
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant (2002) 3.29
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol (2004) 3.10
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol (2010) 2.87
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med (2010) 2.82
The gene encoding R-spondin 4 (RSPO4), a secreted protein implicated in Wnt signaling, is mutated in inherited anonychia. Nat Genet (2006) 2.81
Advocacy groups as research organizations: the PXE International example. Nat Rev Genet (2007) 2.72
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol (2005) 2.64
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood (2004) 2.63
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant (2007) 2.60
In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med (2003) 2.59
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol (2008) 2.55
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood (2008) 2.53
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. Tissue Eng Part A (2010) 2.44
Pseudoxanthoma elasticum is a metabolic disease. J Invest Dermatol (2008) 2.35
Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms. Exp Dermatol (2008) 2.35
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum. J Med Genet (2007) 2.32
Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 2.31
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood (2004) 2.28
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
Acute graft-versus-host disease: from the bench to the bedside. Blood (2009) 2.24
In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood (2008) 2.24
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23
The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol (2013) 2.22
Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum (2009) 2.20
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med (2013) 2.18
Leukocyte migration and graft-versus-host disease. Blood (2005) 2.17
Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood (2009) 2.15
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Pseudoxanthoma elasticum is a recessive disease characterized by compound heterozygosity. J Invest Dermatol (2006) 2.14
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood (2007) 2.12
Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris. Cell (2003) 2.06
Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol (2006) 2.05
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03
Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nat Genet (2008) 2.00
Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet (2004) 1.99
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood (2003) 1.97
Mutations in the lipase H gene underlie autosomal recessive woolly hair/hypotrichosis. J Invest Dermatol (2008) 1.96
Aberrant mineralization of connective tissues in a mouse model of pseudoxanthoma elasticum: systemic and local regulatory factors. J Invest Dermatol (2007) 1.93
Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood (2006) 1.92
Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood (2005) 1.89